James French Hill
Tickers in This Filing
Price Movement Since Trade
How each stock has moved from the trade date to the most recent close.
Suspicious Timing Detected
4 flagsRep. James French Hill sold $100,001-$250,000 in $PFE on 2025-12-31, 71 days before HR7902, a bill to withdraw FDA approval for mifepristone, was introduced on 2026-03-12.
Rep. James French Hill sold $100,001-$250,000 in $PFE on 2025-12-31, 75 days before S4104, a bill to establish a database for corporate offenses, was introduced on 2026-03-16.
These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
| Type | Ticker | Asset | Amount | Trade Price | Current | Change | Date |
|---|---|---|---|---|---|---|---|
| SELL | $PFE | Pfizer, Inc. Common Stock | $100K-$250K | $24.90 | $25.93 | +4.1% | Dec 31, 2025 |
| SELL | $SFL | SFL Corporation Ltd | $15K-$50K | $7.81 | $12.67 | +62.2% | Dec 31, 2025 |
| SELL | $SOLV | Solventum Corporation Common Stock | $15K-$50K | $79.24 | $75.47 | -4.8% | Dec 31, 2025 |
| SELL | $KD | Kyndryl Holdings, Inc. Common Stock | $1K-$15K | $26.56 | $11.73 | -55.9% | Dec 31, 2025 |
Connected Legislative Activity
10 signalsThese bills and contracts share tickers or sectors with this filing's trades.
Protecting Americans from Unsafe Drugs Act of 2026
The Protecting Americans from Unsafe Drugs Act of 2026 (HR7980) would expand FDA mandatory recall authority from controlled substances to all drugs, increasing structural operational risk and compliance costs for major pharmaceutical manufacturers. The bill is at an early legislative stage with a single Democratic sponsor, giving it low near-term passage probability. Market data shows the sector is already under pressure in April 2026 with JNJ, PFE, MRK, and AZN all down significantly over 30 days, but this bill is not yet being priced in as a material risk.
DLA TROOP SUPPORT: $65.0M Department of Health and Human Services Contract
This $65.0 million contract for pharmaceuticals and related supplies, awarded to DLA Troop Support by the NIH, is likely to benefit major pharmaceutical companies as prime or sub-contractors, driven by ongoing federal healthcare needs. The award aligns with legislative support for healthcare services, suggesting a stable demand environment.
A bill to direct the Director of the Bureau of Justice Statistics to establish a database with respect to corporate offenses, and for other purposes.
The Corporate Crime Database Act of 2026 (S.4104) is an early-stage, unfunded bill that would create a public database of federal corporate enforcement actions. With no appropriations and a procedural status in the Judiciary Committee, the bill poses no immediate financial liability for any company. However, it increases reputational risk visibility for major banks with extensive regulatory histories, including JPMorgan, Bank of America, and Wells Fargo. Market impact is minimal in the near term — BAC trades at $52.88 (7-day +0.78%) and WFC at $81.51 (7-day +1.24%), reflecting no reaction to this bill.
To amend title XVIII of the Social Security Act to require PDP sponsors of a prescription drug plan under part D of the Medicare program that use a formulary to include certain generic drugs and biosimilar biological products on such formulary, and for other purposes.
HR8143 mandates Medicare Part D formularies give preferred placement to generic drugs and biosimilars with lower wholesale acquisition costs than brand-name reference products, effective January 1, 2027. This directly benefits pure-play generics manufacturers $VTRS and $TEVA by guaranteeing formulary access and restricting PBM utilization management. The bill is early stage (referred to committee) but has bipartisan sponsorship and clear structural impact on the Part D market.
Strengthening the Vaccines for Children Program Act of 2026
HR8425 is an early-stage authorization bill that expands VFC eligibility and mandates minimum Medicaid vaccine administration reimbursement rates, but it contains no funding appropriations. Market data shows no price reaction from PFE or MRNA following introduction. The bill is unlikely to generate material revenue changes for vaccine manufacturers without separate appropriations bills.
Maternal Vaccination Act
HR8024 authorizes $85M total over 5 years for maternal vaccination awareness campaigns - an amount too small to move revenue for major vaccine manufacturers. The bill has one sponsor (Rep. Sewell, D-AL), was referred to committee on 2026-03-19, and has no appropriations guarantee. No market impact.
To provide that the approved application under the Federal Food, Drug, and Cosmetic Act for the drug mifepristone for the purpose of the termination of intrauterine pregnancy is deemed to have been withdrawn, to establish a Federal tort for harm to women caused by chemical abortion drugs, and for other purposes.
HR 7902 (Safeguarding Women from Chemical Abortion Act) would withdraw FDA approval for mifepristone for pregnancy termination and create a federal tort for harm from chemical abortion drugs. The bill was introduced March 12, 2026, referred to two committees, and is in early legislative stages with only 6 cosponsors. Revenue exposure for $PFE and $TEVA is immaterial to their overall financials — less than 0.1% of revenue for each. The bill has effectively no near-term market impact.
End Veterans Overdose Act of 2026
The End Veterans Overdose Act mandates the VA to provide free opioid rescue medication to veterans and caregivers. This creates a guaranteed procurement channel within the VA system, but the generic nature of naloxone and the relatively small patient population mean no single company sees a transformative revenue catalyst. CVS may see modest incremental dispensing volume.
Maternal Vaccinations Act
The Maternal Vaccinations Act (S. 4132) is an early-stage authorization bill increasing maternal vaccination awareness funding by $2M/year to $17M/year for FY2027-2031. This is a procedural move with no near-term market impact — actual funding requires separate appropriations, and the dollar amount is immaterial to vaccine manufacturers like $MRNA, $PFE, and $GSK.
To amend title XVIII of the Social Security Act to ensure equitable payment for, and preserve Medicare beneficiary access to, cancer treatments under the Medicare hospital outpatient prospective payment system.
HR8032 (FAIC Act) is an early-stage bill requiring separate Medicare Part B payment for qualifying cancer drugs, eliminating a hospital incentive to avoid expensive branded oncology therapies. The bill protects $50B+ in oncology drug revenue for major pharma companies but faces a long legislative path through two committees. Current stock prices for affected tickers are near the bottom of their 52-week ranges, suggesting market pessimism is already priced in, creating asymmetric upside if the bill advances.
Other Filings by James French Hill
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.